Hepatitis C comorbidities affecting the course and response to therapy.
Several studies have demonstrated that the outcome of chronic hepatitis C (CHC) infection is profoundly influenced by a variety of comorbidities. Many of these comorbidities have a significant influence on the response to antiviral therapy. These comorbidities negatively affect the course and outcome of liver disease, often reducing the chance of achieving a sustained virological response with PEGylated interferon and ribavirin treatments. Comorbidities affecting response to antiviral therapy reduce compliance and adherence to inadequate doses of therapy. The most important comorbidities affecting the course of CHC include hepatitis B virus coinfection, metabolic syndrome, and intestinal bacterial overgrowth. Comorbidities affecting the course and response to therapy include schistosomiasis, iron overload, alcohol abuse, and excessive smoking. Comorbidities affecting response to antiviral therapy include depression, anemia, cardiovascular disease, and renal failure.
Abdel-Rahman
AR
El-Zayadi
D000437:Alcoholism / Q000150:complications; D000998:Antiviral Agents / Q000494:pharmacology; D015897:Comorbidity; D005762:Gastroenterology / Q000379:methods*; D006526:Hepatitis C / Q000150:complications* / Q000628:therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D019190:Iron Overload / Q000150:complications; D011092:Polyethylene Glycols / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use; D012552:Schistosomiasis / Q000150:complications; D012907:Smoking; D016896:Treatment Outcome
D000998:Antiviral Agents; D011092:Polyethylene Glycols; D012254:Ribavirin; D007372:Interferons